Zobrazeno 1 - 10
of 226
pro vyhledávání: '"Erkut Borazanci"'
Autor:
Gayle S. Jameson, Peter J. Hosein, Erin Pierce, Mandana Kamgar, Michael S. Gordon, Courtney Snyder, Denise J. Roe, Betsy C. Wertheim, Marina Davey, Michael T. Barrett, Daniel D. Von Hoff, Erkut Borazanci
Publikováno v:
Cancer Medicine, Vol 13, Iss 12, Pp n/a-n/a (2024)
Abstract Background A previous phase IB/II study of nab‐paclitaxel + cisplatin + gemcitabine (NABPLAGEM) in 25 patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC) demonstrated favorable results. This phase II study
Externí odkaz:
https://doaj.org/article/2c0e7f0b47f441ccb1349c0b69fa9034
Autor:
Corina E. Antal, Tae Gyu Oh, Stefan Aigner, En-Ching Luo, Brian A. Yee, Tania Campos, Hervé Tiriac, Katherine L. Rothamel, Zhang Cheng, Henry Jiao, Allen Wang, Nasun Hah, Elizabeth Lenkiewicz, Jan C. Lumibao, Morgan L. Truitt, Gabriela Estepa, Ester Banayo, Senada Bashi, Edgar Esparza, Ruben M. Munoz, Jolene K. Diedrich, Nicole M. Sodir, Jasmine R. Mueller, Cory R. Fraser, Erkut Borazanci, David Propper, Daniel D. Von Hoff, Christopher Liddle, Ruth T. Yu, Annette R. Atkins, Haiyong Han, Andrew M. Lowy, Michael T. Barrett, Dannielle D. Engle, Gerard I. Evan, Gene W. Yeo, Michael Downes, Ronald M. Evans
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-17 (2023)
Abstract Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy in need of new therapeutic options. Using unbiased analyses of super-enhancers (SEs) as sentinels of core genes involved in cell-specific function, here we uncover a druggable SE
Externí odkaz:
https://doaj.org/article/57cc744cc0404cd39ed1bebee4e6eee7
Autor:
Faithlore P. Gardner, Zev A. Wainberg, Christos Fountzilas, Nathan Bahary, Mark S. Womack, Teresa Macarulla, Ignacio Garrido-Laguna, Patrick M. Peterson, Erkut Borazanci, Melissa Johnson, Matteo Ceccarelli, Uwe Pelzer
Publikováno v:
Cancers, Vol 16, Iss 7, p 1323 (2024)
The efficacy and safety of olaratumab plus nabpaclitaxel and gemcitabine in treatment-naïve participants with metastatic pancreatic ductal adenocarcinoma was evaluated. An initial phase 1b dose-escalation trial was conducted to determine the olaratu
Externí odkaz:
https://doaj.org/article/a853f4e8e50e44b0a0a9e297a6693aed
Role of 3D Volumetric and Perfusion Imaging for Detecting Early Changes in Pancreatic Adenocarcinoma
Autor:
Syed Rahmanuddin, Ronald Korn, Derek Cridebring, Erkut Borazanci, Jordyn Brase, William Boswell, Asma Jamil, Wenli Cai, Aqsa Sabir, Pejman Motarjem, Eugene Koay, Anirban Mitra, Ajay Goel, Joyce Ho, Vincent Chung, Daniel D. Von Hoff
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
PurposeThere is a major shortage of reliable early detection methods for pancreatic cancer in high-risk groups. The focus of this preliminary study was to use Time Intensity-Density Curve (TIDC) and Marley Equation analyses, in conjunction with 3D vo
Externí odkaz:
https://doaj.org/article/7e5edb490b994c4494db038e364f5410
Autor:
Margaret Y. Han, Erkut Borazanci
Publikováno v:
Journal of Gastrointestinal Oncology. 14:458-462
Autor:
Gerald Falchook, Jeffrey Infante, Hendrik-Tobias Arkenau, Manish R. Patel, Emma Dean, Erkut Borazanci, Andrew Brenner, Natalie Cook, Juanita Lopez, Shubham Pant, Arthur Frankel, Peter Schmid, Kathleen Moore, William McCulloch, Katharine Grimmer, Marie O'Farrell, George Kemble, Howard Burris
Publikováno v:
EClinicalMedicine, Vol 34, Iss , Pp 100797- (2021)
Background: We conducted a first-in-human dose-escalation study with the oral FASN inhibitor TVB-2640 to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D), as monotherapy and with a taxane. Methods: This completed open-la
Externí odkaz:
https://doaj.org/article/2febb21dda0b44dcb8507b74f4dd5b16
Autor:
Antoine Hollebecque, Rocio Garcia-Carbonero, Do-Youn Oh, Emiliano Calvo, Davide Melisi, Teresa Macarulla, Valeria Merz, Erkut Borazanci, Anna Varghese, Camilla Zecchetto, Yumin Zhao, Ivelina Gueorguieva, Michael Man, Shawn T Estrem, Karim A Benhadji, Emin Avsar, Susan C Guba
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Background We assessed the safety, efficacy, and pharmacokinetics of the transforming growth factor beta (TGFβ) receptor inhibitor galunisertib co-administered with the anti-programmed death-ligand 1 (PD-L1) antibody durvalumab in recurrent/refracto
Externí odkaz:
https://doaj.org/article/c175cf79b75445f3ae95a488c7252728
Autor:
Anh Nguyen, Adi Diab, Brendan Curti, Jonathan Zalevsky, Mary Tagliaferri, Christie Fanton, Evidio Domingo-Musibay, Wei Lin, Mehmet Bilen, Sandra D’Angelo, Andrew Brohl, Erkut Borazanci, Cat Haglund, Mona Vimal, Mann Muhsin, Mario Marcondes
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/4bbc8e2cb9964df1970c89d62cae7e95
Autor:
Manuel Hidalgo, Rocio Garcia-Carbonero, Kian-Huat Lim, Wells A. Messersmith, Ignacio Garrido-Laguna, Erkut Borazanci, Andrew M. Lowy, Laura Medina Rodriguez, Daniel Laheru, Beatriz Salvador-Barbero, Marcos Malumbres, David J. Shields, Joseph E. Grossman, Xin Huang, Meggan Tammaro, Jean-François Martini, Yanke Yu, Kenneth Kern, Teresa Macarulla
Publikováno v:
Cancer Research Communications. 2:1326-1333
Purpose: To assess the preclinical efficacy, clinical safety and efficacy, and MTD of palbociclib plus nab-paclitaxel in patients with advanced pancreatic ductal adenocarcinoma (PDAC). Experimental Design: Preclinical activity was tested in patient-d
Autor:
Pamela N. Munster, Andrew E. Greenstein, Gini F. Fleming, Erkut Borazanci, Manish R. Sharma, Joseph M. Custodio, Iulia Cristina Tudor, Hristina I. Pashova, Stacie Peacock Shepherd, Andreas Grauer, Jasgit C. Sachdev
Publikováno v:
Clinical Cancer Research. 28:3214-3224
Purpose: Chemotherapy resistance remains a major problem in many solid tumors, including breast, ovarian, and pancreatic cancer. Glucocorticoids are one potential driver of chemotherapy resistance as they can mediate tumor progression via induction o